NSE: ADVENZYMES | BSE: 540025

Mid-range Performer

Download real time

308.95 2.00 (0.65%)

45.89% Fall from 52W High

240.7K NSE+BSE Volume

NSE 14 Aug, 2025 2:01 PM (IST)

3,456.6

Market Cap

Below industry Median

1.0

Beta 1Year

Average volatility

Advanced Enzyme Technologies Ltd. share price target and research reports

Name: Latest research reports of Advanced Enzyme Technologies Ltd. authored by Emkay and published by - Trendlyne research reports.
Item: Advanced Enzyme Technologies Ltd.
Rating: 5
Author: Emkay

Latest analyst research reports with target prices and PDF download for ADVENZYMES, BSE:540025 Advanced Enzyme Technologies Ltd.

Advanced Enzyme Technologies Ltd.

05 Nov 2019

308.95

0.65%

ADVENZY delivered topline growth of 8% yoy to Rs1.11bn in Q2FY20, largely in line with ou...

Buy: Advanced Enzyme Technologi...

Target

Emkay

ADVENZY delivered topline growth of 8% yoy to Rs1.11bn in Q2FY20, largely in line with our estimates. EBITDA margins improved by 158bps yoy to 42.4% due to better operational efficiencies. PAT increased by 25% yoy to Rs310mn. On the segmental front, Human Healthcare grew 7% yoy, Animal HealthCare rose 9% yoy and Bio processing clocked 13% yoy growth. On the geographical front, Europe and India have done well with 51% and 14% yoy growth, respectively. its clients amid a weak economy. However, it remains confident of achieving ~10% yoy revenue growth and EBITDA margins in the range of 41-45% for FY20....

Advanced Enzyme Technologies Ltd.'s price crossed above 100Day SMA today

Advanced Enzyme Technologies Ltd.

21 May 2018

308.95

0.65%

Advanced Enzymes' (ADVENZY) Q4FY18 results were in line with our estimate. Revenue stood...

Buy: Advanced Enzyme Technologi...

Emkay

Advanced Enzymes' (ADVENZY) Q4FY18 results were in line with our estimate. Revenue stood at Rs1.08bn, up 26% yoy (Emkay Est: Rs1.08bn). US, India, Asia, Europe and Others geographies grew by 36%, 7%, 281%, 27% and 154% yoy, respectively. Revenue growth was driven by Human Nutrition (+36% yoy | 76% of revenue), Industrial Processing (+27% yoy | 5% of Rev.) and Animal Healthcare (5% yoy | 14% of Rev);...

Advanced Enzyme Technologies Ltd. has lost -25.85% in the last 1 Year

Advanced Enzyme Technologies Ltd.

19 Sep 2017

308.95

0.65%

Advance Enzyme Technologies - IPO

Mgmt Note: Advanced Enzyme Technologi...

ICICI Securities Limited

We met the management of Advanced Enzyme Technologies (AET) to understand its business model and future prospects. AET is one of the largest research driven Indian enzyme companies with more than two decades of experience in the fermentation process for producing enzymes. It is engaged in the R&D;, manufacturing and marketing of more than 400 proprietary enzyme products developed from 68+ indigenous enzymes operating in two primary business verticals viz. 1) healthcare and nutrition: human (72% of revenue) animal (15%) and 2) bioprocessing: food (7%) and non-food (6%). It offers these products to...

Advanced Enzyme Technologies Ltd. has lost -25.85% in the last 1 Year

Advanced Enzyme Technologies Ltd.

04 Jul 2017

308.95

0.65%

ADVANCED ENZYME TECHNOLOGIES LTD.

Not Rated: Advanced Enzyme Technologi...

Ventura

Company Update

FII/FPI have increased holdings from 11.90% to 23.45% in Jun 2025 qtr.

Advanced Enzyme Technologies Ltd.

19 Jul 2016

308.95

0.65%

IPO Note - Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologi...

HDFC Securities

Advanced Enzyme Technologies Ltd (AETL) is the largest Indian enzyme company, engaged in
the research and development, manufacturing and marketing of 400+ proprietary products
developed from 60 indigenous enzymes. AETL ranks among the top 15 global companies in
terms of enzyme sales, and has the second highest market share domestically, next only to the
world’s largest enzyme company Novozymes and operates in two primary business verticals
namely Healthcare & Nutrition (human and animal) and Bio-Processing (food and non-food). It
is a fully integrated enzyme manufacturing company driven by extensive focus on research and
development (“R&D”) of various enzymes, enzyme blends, enzyme products and customized
enzyme solutions. Its experienced and qualified R&D team strives to develop creative, cost-
effective unique and innovative solutions, thereby enabling its customers to develop superior
products and processes.

 

FII/FPI have increased holdings from 11.90% to 23.45% in Jun 2025 qtr.

Advanced Enzyme Technologies Ltd.

19 Jul 2016

308.95

0.65%

Advance Enzyme Technologies - IPO

Advanced Enzyme Technologi...

ICICI Securities Limited

Advanced Enzyme Technologies (AET) is one of the largest research driven Indian enzyme companies with more than two decades of experience in the fermentation process for production of enzymes. It is engaged in R&D, manufacturing and marketing of more than 400 proprietary enzyme products developed from 60 indigenous enzymes operating in two primary business verticals namely healthcare and nutrition (human and animal) and bio-processing (food and non-food). It offers these products to a global clientele of more than 700 customers across 50 countries worldwide. The company manufactures enzymes by using all four existing natural origins viz. plant, fungal, bacterial and animal sources, using environment-friendly biotechnology processes.At the IPO price band of | 880-896, the stock is available at 25.5-29.6x of FY16 EPS of | 35.1-29.6.

Advanced Enzyme Technologies Ltd.'s price crossed above 100Day SMA today

Advanced Enzyme Technologies Ltd.

18 Jul 2016

308.95

0.65%

IPO Note - Advanced Enzymes Tech

ipo note: Advanced Enzyme Technologi...

Aditya Birla Money Limited

FII/FPI have increased holdings from 11.90% to 23.45% in Jun 2025 qtr.

Advanced Enzyme Technologies Ltd.

18 Jul 2016

308.95

0.65%

Advanced Enzyme Technologies Limited

Advanced Enzyme Technologi...

Angel Broking

Advanced Enzyme Technologies (AET) is the second largest enzyme company in India and amongst the Top 15 global enzyme companies with a market share of ~0.9%. The company is engaged in research & development, manufacturing and marketing of 400+ proprietary products developed from 60 indigenous enzymes. Specialized business with high en..

Institutional Investors have increased holdings from 20.09% to 31.90% in Jun 2025 qtr.

Is Advanced Enzyme Technologies Ltd. worth buying?

344 Votes:

Buy 84.01%

Sell 11.05%

Hold 4.94%